Literature DB >> 2793977

Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.

M A Graham1, D R Newell, A H Calvert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2793977     DOI： 10.1016/s0378-4347(00)82841-8

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  4 in total

1.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology.

Authors:  S G Allan; J Cummings; S Evans; M Nicolson; M E Stewart; J Cassidy; M Soukop; S B Kaye; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

Authors:  B C Goh; E E Vokes; A Joshi; M J Ratain
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.